Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Power Metal hits "bullseye"; Instem makes acquisition

Wed, 01st Sep 2021 19:34

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Power Metal Resources PLC - gold and base metals explorer with assets in North America, Australia and Africa - Identifies a "bullseye" geophysical anomaly at the First Development Resources Pty Ltd copper-gold projects in Australia which Power Metal is in the process of buying. A phase 1 work programme is now being finalised, and plans to list a UK holding company for the assets, FDR UK, are continuing.

----------

Greatland Gold PLC - gold explorer in Australia - Reports preliminary results from the 2021 drilling programme at the Juri joint venture in the Paterson province, Western Australia. The first four of nine holes show gold mineralisation. The results from the remaining holes are expected in October. A ground electromagnetic survey is due to start this month. "Intercepting gold mineralisation from our initial assays is an excellent result. Greatland will now recalibrate our Juri JV targets based on this initial information as well as the assays pending from the five remaining drill holes and combined with the new proposed ground EM survey," Chief Executive Shaun Day says.

----------

Galileo Resources PLC - London-based gold and base metals explorer - Amends deal to sell the Kalahari Copper Belt licences to Sandfire Resources Ltd, extending the long stop date to September 15. The extension will give the companies time to obtain ministerial consent. All other conditions for the sale have been met.

----------

Mirriad Advertising PLC - London-based advertising technology - Signs partnership agreement with Looping Group, a German advertising agency. The two companies will develop and introducer plan covering prospective clients. Mirriad will bring its services to Looping's clients including Mercedes-Benz, Allianz SE and Deutsche Telekom AG.

----------

Seed Innovations Ltd - investor in pharmaceutical companies - Notes that portfolio company Little Green Pharma Ltd, in which Seed owns 3.1%, released its results for the financial year ended June 30. LGP made AUD7.0 million revenue, equivalent to GBP3.7 million. LGP made pretax profit of AUD24.6 million, reflecting an uplift to the value of a facility in Denmark.

----------

BP Marsh & Partners PLC - investor in financial services companies - MB Prestige Holdings Pty Ltd is sold to ATC Insurance Solutions Pty Ltd for AUD17 million, around GBP9 million. BP Marsh agrees to swap its 40% stake in MB Prestige for newly issued ATC Insurance shares. As a result, BP Marsh's stake in ATC Insurance will increase to 26% from 20%. The transaction represents a 20% uplift in BP Marsh's latest published valuation of its MB Prestige stake on January 31, of AUD5.7 million.

----------

Semper Fortis Esports PLC - London-based esports teams operator - Signs 20-year-old Thibault Grzesiak for the SMPR Rocket League team. The team is now complete and ready for the new season. Financial terms of the deal are not disclosed.

----------

Tissue Regenix Group PLC - Leeds-based wound treatment products - Launches two new products, DermaPure Meshed and VNEW, both line extensions to the biosurgery division. DermaPure meshed provides surgeons with a customised option that eliminates manual meshing in the operating room. VNEW is a pre-shaped, pre-cut acellular dermal allograft. Tissue Regenix has already fulfilled its initial stocking order for VNEW.

----------

Riverstone Credit Opportunities Income PLC - investor in debt - Invests USD12.5 million in a USD100.0 million first lien green term loan to a polyethylene recycling company. The loan matures in August 2024 and has an expected all-in yield to maturity of 13.5%. This is Riverstone Credit's first green loan, and it plans to use similar lending structures in future.

----------

Vaalco Energy Inc - Houston-based oil producer in Gabon and Equatorial Guinea - Agreements with World Carrier Offshore Services Corp are now effective after joint venture partners approve. Last Thursday, Vaalco announced the deals to rent a floating storage and offloading unit at the Etame Marin Field in Gabon.

----------

Altus Strategies PLC - mining royalties investor - Drilling confirms the discovery of a significant zone of gold mineralisation at the Tabakorole project in Mali. Altus holds a 49% stake and 2.5% net smelter return on Tabakorole. The results are expected to increase the volume and grade of the mineral resource estimate.

----------

Diurnal Group PLC - Cardiff-based hormone drug developer - Launches Efmody, a treatment for congenital adrenal hyperplasia, in Germany and Austria. Pricing is in line with the company's expectations. Diurnal is in talks with health authorities across the European Economic Area for further launches.

----------

Instem PLC - Staffordshire-based healthcare software - Buys Basel, Switzerland-based life sciences software company PDS Pathology Data Systems Ltd for a total enterprise value of CH14.3 million, around GBP11.4 million, in cash and shares. The deal will deepen Instem's relationship with some of its largest clients and be immediately earnings-enhancing, Instem says.

----------

TomCo Energy PLC - oil explorer in Utah - Amends terms of the deal to buy Tas Sands Holdings II LLC. TomCo now has until October 1 to exercise its right to buy an initial 10% of Tar Sands for USD2 million, extended from September 1. TomCo paid a USD100,000 deposit for the extension.

----------

MetalNRG PLC - investor in energy and precious metals projects - 50%-owned joint venture BritNRG is now profitable following operational improvements in the first half of 2021. The venture is producing 3,500 barrels of oil per month, versus less than 1,500 barrels per month in the first quarter. BritNRG sold 3,780 barrels in July at an average price of USD73.88 each. Revenue from the Whisby site is forecast to be over USD2.5 million per year.

----------

By Ivan Edwards; ivanedwards@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
10 Jan 2019 11:33

Diurnal Shares Surge As Secures Second Patent For Chronocort In US

LONDON (Alliance News) - Diurnal Group PLC on Thursday said the US Patent & Trademark Office has granted the company a second US patent for Chronocort.Diurnal shares almost tripled on a

Read more
10 Jan 2019 11:26

Diurnal awarded US patent for Chronocort product

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Thursday that the US Patent and Trademark Office (USPTO) has granted a second US patent for its 'Chronocort' modified release hydrocortisone product.

Read more
17 Oct 2018 12:10

Diurnal halts US development of Chronocort after European trials come up short

(Sharecast News) - Speciality pharmaceutical company Diurnal has put all development activities for its modified release hydrocortisone product on hold after it failed to meet its primary endpoint in a recent phase-three European trial.

Read more
17 Oct 2018 10:41

Diurnal Puts All Chronocort US Development Activities On Hold

LONDON (Alliance News) - Diurnal Group PLC said Wednesday it decided to put all US development activities for its Chronocort product on hold, after it failed to meet its primary objective in its a

Read more
8 Oct 2018 17:07

LONDON MARKET CLOSE: Stocks End Lower On Chinese And Italian Woes

LONDON (Alliance News) - Stocks closed lower Monday on the actions of the Chinese and Italian governments, as the pound continued its fall on news from 10 Downing Street there remains "big in of

Read more
8 Oct 2018 15:15

Diurnal Group Child Adrenal Insufficiency Drug Approved In Scotland

LONDON (Alliance News) - Diurnal Group PLC said Monday the Scottish Medicines Consortium approved the routine use of Alkindi, a first-line treatment of young children with adrenal insufficiency to

Read more
8 Oct 2018 12:00

LONDON MARKET MIDDAY: China Prompts Sell-Off In Europe; Insurers Fall

LONDON (Alliance News) - Share prices in London had slipped firmly into the red by midday on Monday following a slump in Chinese equities overnight."Europe is following the Asian lead, with a 3%

Read more
8 Oct 2018 10:33

WINNERS & LOSERS SUMMARY: French Connection In Vogue On Possible Sale

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 1.0%. The asset manager confirmed it is in to

Read more
8 Oct 2018 09:29

Diurnal's endocrine drug does not meet trial objective

(Sharecast News) - Clinical trials of Diurnal Group's Chronocort drug failed to meet the primary objective of proving superior to conventional therapy in endocrine control over a 24-hour period.

Read more
8 Oct 2018 08:54

Shares In IP Group, Diurnal Suffer After Chronocort Trial Disappoints

LONDON (Alliance News) - Diurnal Group PLC said Monday its phase-three European trial of Chronocort did not meet its primary objective, causing shares in the pharmaceutical company to property IP

Read more
8 Oct 2018 07:48

LONDON MARKET PRE-OPEN: Lower Call; Schroders Confirms Lloyds Talks

LONDON (Alliance News) - Stocks in London on Monday are set to continue last week's slide, fuelled by concerns that strong US economic data will lead to a quickened pace of interest rate hikes.In

Read more
5 Oct 2018 09:20

Diurnal kicks off adrenal condition trial with first patients

(Sharecast News) - Specialist pharmaceutical company Diurnal said it had enrolled the first two patients in its US-based Chronocort phase III trial for adults with congenital adrenal hyperplasia (CAH).

Read more
5 Oct 2018 08:16

Diurnal Enrols First Patients In Phase Three US Chronocort Trial

LONDON (Alliance News) - Pharmaceutical company Diurnal Group PLC on Friday said the first two patients have been enrolled into its phase three US trial of Chronocort.Chronocort is a form a

Read more
20 Sep 2018 09:56

Diurnal Generates First Revenue But Loss Deepens As Costs Rise

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC said Thursday its annual loss deepened amid higher costs despite generating its first revenue from drug sales.For the year the

Read more
15 Aug 2018 12:39

German Body Says Diurnal Alkindi's Benefit Over Generic Not Proven

LONDON (Alliance News) - Diurnal Group PLC said Wednesday a German body published a study which says that the benefit of the company's product Alkindi over generic hydrocortisone has not been

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.